All In Biotech

Drug Trial Radar · NCT06021678

Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

A Phase I/II Study Evaluating the Safety, Efficacy, and Pharmacokinetics of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

Last checked: Nov 19, 2026Latest source record: Feb 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

415

Planned (sponsor's estimate)

Start

Nov 12, 2021

Primary completion

Oct 2025

Study completion Dec 2025

Sponsor

Lead sponsor
Guangzhou Excelmab Inc.Industry
Sponsor type
Industry
First posted
Sep 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, single-arm, open, dose-escalation Phase I/II clinical trial, consisting of a dose-escalation phase (accelerated titration phase, 3+3 design) and a dose expansion phase.

Conditions

  • CD20-positive Non-Hodgkin Lymphoma

Interventions

  • EX103 injectionDrug

    Administered as specified in the treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose Limiting Toxicities (DLTs) [dose escalation (Cycle 0 and Cycle 1)]Time frame: During the DLT evaluation period (28 days from Cycle1 Day1 at the dose escalation stage).
  2. Safety endpoints:incidence and severity of adverse events (AE), laboratory tests, etc.Time frame: From first dose until the end of the safety follow-up period [within 28 ± 7 days after the last study treatment or before the start of other anti-tumor treatments (whichever occurs earlier)].

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Affiliated to Zhengzhou University, Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Qilu Hospital, Cheeloo College of Medicine, Shandong University

    Jinan, Shandong, China · Recruiting

  • Shanghai Sixth People's Hospital, Shanghai Jiaotong University school of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

  • Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.